ライフサイエンスコーパス: protein p53

1 ed additionally for the tumor suppressor p53 protein (p53).

2 rization domain (TD) of the tumor suppressor protein p53.

3 ovarian tumor cell lines not expressing the protein p53.

4 one proteins, including the tumor suppressor protein p53.

5 SET8/PR-Set7 regulates the tumor suppressor protein p53.

6 criptional network of human tumor suppressor protein p53.

7 rylating and activating the tumor-suppressor protein p53.

8 in is known to regulate the tumor suppressor protein p53.

9 causes a rapid stabilization of the cellular protein p53.

10 for the proper function of tumor suppressor protein p53.

11 y rescued by removal of the tumor suppressor protein p53.

12 apoptosis downstream of the tumor-suppressor protein p53.

13 scriptional activity of the tumor suppressor protein p53.

14 cally disordered tetrameric tumor suppressor protein p53.

15 hibitory cytokines and the tumour-suppressor protein p53.

16 hibitor of signaling by the tumor suppressor protein p53.

17 proline-rich domain of the tumor suppressor protein p53.

18 a checkpoint involving the tumor suppressor protein p53.

19 es and hence stabilizes the tumor suppressor protein p53.

20 crease in the expression of the proapoptotic protein p53.

21 the proapoptotic BAX is the tumor suppressor protein p53.

22 ctivity is repressed by the tumor suppressor protein p53.

23 apid elevations of the DNA damage-responsive protein p53.

24 in a complex stabilized by tumor suppressor protein p53.

25 atures of activation of the tumor-suppressor protein p53.

26 int independently of the 'tumour suppressor' protein p53.

27 iptionally regulated by the tumor suppressor protein p53.

28 egradation of the cellular tumour-suppressor protein p53.

29 l negative regulator of the tumor suppressor protein p53.

30 teraction with the cellular tumor suppressor protein p53.

31 rous proteins including the tumor suppressor protein p53.

32 PARgamma, NFkappaB, and the tumor suppressor protein p53.

33 TP53, the gene encoding the tumor-suppressor protein p53.

34 d and oxidized forms of the tumor suppressor protein p53.

35 V induce the degradation of tumor suppressor protein p53.

36 utations in KRAS, BRAF, or PIK3CA, and tumor protein p53.

37 to assess mutations in the tumour-suppressor protein, p53.

38 target proteins such as the tumor suppressor protein, p53.

39 scription factors including the proapoptotic protein, p53.

40 interacts directly with the tumor suppressor protein, p53.

41 scriptional activity of the tumor suppressor protein, p53.

42 s ability to bind the human tumor suppressor protein, p53.

43 sed for the presence of the tumor suppressor protein, p53.

44 sion by down-regulating the tumor suppressor protein, p53.

45 The mutant protein p53(143V-->A) was inactive.

46 sulted in a frame shift and a 420 amino acid protein (p53(420)).

47 to form a complex with the tumor suppressor protein p53, a known inducer of apoptosis, thereby stabi

48 the protective role of the tumor suppressor protein p53, a nuclear phosphoprotein and transcription

49 tivity and stability of the tumor suppressor protein p53--a cellular process initiated by MDM2 and/or

50 nce of Myc, AMPK-stabilized tumor suppressor protein p53 accumulates in the mitochondria and interact

51 The principal tumour-suppressor protein, p53, accumulates in cells in response to DNA da

52 The tumor suppressor protein p53 acts as a transcription factor, binding sequ

53 inds to and inactivates the tumor suppressor protein p53, allowing efficient replication of the virus

54 The tumour suppressor protein p53 (also known as TP53) influences a range of c

55 and increased levels of the tumor suppressor protein p53 and a cell cycle inhibitor protein p21 (Waf1

56 tivity and stability of the tumor suppressor protein p53 and are important molecular targets for anti

57 th the up-regulation of the tumor suppressor protein p53 and concurrent up-regulation of the cyclin-d

58 affects the binding of the tumour suppressor protein p53 and correlates with decreased expression of

59 by decreasing levels of the tumor suppressor protein p53 and downstream target genes.

60 e in the expression of tumor suppressor gene protein p53 and elevation of the level of cyclin-depende

61 an form complexes with the tumour-suppressor protein p53 and generate high levels of reactive oxygen

62 53BP1 binds to the tumor suppressor protein p53 and has a potential role in DNA damage respo

63 the interaction between the tumor suppressor protein p53 and its negative regulators MDM2 and MDMX is

64 delivered recombinant human tumor suppressor protein p53 and its tumor-selective supervariant into ta

65 geal adenocarcinomas have mutations in tumor protein p53 and mutations that activate receptor-associa

66 ins such as annexin A2, the tumor-suppressor protein p53 and myosin IIA.

67 with the activators of the tumor suppressor protein p53 and NF-kappaB-p65, suggesting similar mechan

68 d to significantly increase tumor suppressor protein p53 and p53-regulated growth-related protein p21

69 3C can directly bind to the tumor suppressor protein p53 and repress its functions, in part by blocki

70 at LANA interacts with the tumour suppressor protein p53 and represses its transcriptional activity.

71 The tumor suppressor protein p53 and the adenoviral 12 S E1A oncoprotein are

72 We investigated the requirements for protein p53 and the ATM gene product in radiation-induce

73 lts in the induction of the tumor suppressor protein p53 and the cdk inhibitor p21.

74 oach was validated with the tumor suppressor protein p53 and the forkhead protein FoxI1 using genomic

75 a pathway that involves the tumor suppressor protein p53 and the mitochondrial translocation of p53.

76 ontaining target sequences in the checkpoint protein p53 and the nonsense-mediated mRNA decay (NMD) p

77 clear complexes between the tumor suppressor protein p53 and the pro-apoptotic protein Bax, in human

78 y be cross talk between the tumor suppressor protein p53 and WISP-1 signaling pathways.

79 that physical interactions of other cellular proteins (p53 and par-4) with WT1 can modulate the funct

80 expression of the zinc-containing DNA-repair proteins p53 and apurinic endonuclease (APE).

81 protein, and up-regulated the pro-apoptotic proteins p53 and Bax.

82 As were ubiquitin, the cell cycle-regulating proteins p53 and mdm-2, HSP70, the global transcriptiona

83 ning, expression of the senescent associated proteins p53 and p16INK4a, and apoptosis of CPCs, impair

84 ly downregulated, while the tumor suppressor proteins p53 and p21 were substantially upregulated foll

85 ressed SA-beta-gal and senescence-associated proteins p53 and p21(WAF1).

86 ncreased expression of senescence-associated proteins p53 and p21(WAF1/CIP1).

87 to the accumulation of the tumor suppressor proteins p53 and p21.

88 of pyridine nucleotides and tumor suppressor proteins p53 and p73, and a decrease in apoptosis.

89 -ag), which inactivates the tumor-suppressor proteins p53 and pRb family members.

90 s and was shown to bind the tumor suppressor proteins p53 and pRb.

91 art, to inactivation of the tumor suppressor proteins p53 and pRB.

92 reover, the expressions of tumour suppressor proteins p53 and PTEN were upregulated along with the do

93 rtners such as the cellular tumor suppressor proteins p53 and Rb, both in vitro and in vivo.

94 and inactivate the cellular tumor suppressor proteins p53 and Rb, respectively.

95 functional activity of the tumor suppressor proteins p53 and RB.

96 part to perturbation of the tumor suppressor proteins p53 and the retinoblastoma (pRB) family members

97 The ability of both tumor suppressor proteins, p53 and BRCA1, to induce the expression of p21

98 tions with DNA binding domains of p53 family proteins, p53 and p73.

99 of somatic mutations in TP53 (encoding tumor protein p53) and PTEN (encoding phosphate and tensin hom

100 in the cell activates the tumour-suppressor protein p53, and failure of this activation leads to gen

101 ng enhanced degradation of tumour suppressor protein p53, and inhibition of gankyrin activity has the

102 ional downregulation by the tumor suppressor protein p53, and this repression can be shown to contrib

103 ensus binding site for the tumour suppressor protein p53, and we show by gel-retardation analysis tha

104 We found induction of tumor suppressor protein, p53, and apoptosis with suppression of urokinas

105 IDPs, such as alpha-synuclein, tau protein, p53, and BRCA1, are attractive targets for drug

106 found to interact with the tumor suppressor protein, p53, and inhibit its PKC-dependent phosphorylat

107 ell cycle, the retinoblastoma-susceptibility protein, p53, and possibly DDX5 and DDX3 lead to enhance

108 tophagy; not reliant on the tumor suppressor protein p53; and effective against mouse models for B-ce

109 nstrate that IRF-1 and the tumour suppressor protein p53 are coordinately up-regulated during the res

110 binding core domain of the tumour suppressor protein p53 are frequent in cancer.

111 Levels of the tumour suppressor protein p53 are increased in response to a variety of DN

112 trigger the induction of the stress response protein p53 are poorly understood but may involve altera

113 Here we identify the tumour-suppressor protein p53 as a COP1-interacting protein.

114 We also identified the tumor suppressor protein p53 as a mediator of podocyte apoptosis in cells

115 rogation of function of the tumor-suppressor protein p53 as a result of mutation of its gene, TP53, i

116 phosphorylation of the p53 tumor suppressor protein (p53) at serine 18, and increased p53 protein le

117 The DNA repair protein p53 binding protein 1 (53BP1) protects the genom

118 by the tandem tudor domain containing tumor protein p53 binding protein 1 (53BP1).

119 e damage-induced recombinase Rad51 and tumor protein P53 binding protein foci formation.

120 e we examine the genome-wide impact of tumor protein P53-binding protein 1 (53BP1) deficiency in lymp

121 MRN and ATM, including the tumour suppressor proteins p53-binding protein 1 (53BP1) and BRCA1.

122 proteins interact with the tumor suppressor protein p53 both in vitro and in vivo.

123 ells harboring a functional tumor suppressor protein p53, but much less efficiently in p53-null mutan

124 are thought to involve the tumor suppressor protein p53, but the degree to which this factor contrib

125 any cancers, stabilizes the tumor suppressor protein p53 by abrogating its MDM2-dependent proteasomal

126 Inactivation of the tumor suppressor protein p53 by mutagenesis, chemical modification, prote

127 Tumor suppressor protein p53 can act as a transcription factor affecting

128 Here we report that the tumor suppressor protein p53 can associate with PXR and downregulate its

129 red, activation of the cell cycle checkpoint protein p53 can lead to apoptosis.

130 rotein, a homologue of the tumour-suppressor protein p53, can activate p53-responsive promoters and i

131 gically important residues on the checkpoint proteins p53, Chk1, and RPA.

132 tivity and stability of the tumor suppressor protein p53, conferring tumor development and survival.

133 erminal BOX-I domain of the tumor suppressor protein p53 contains the primary docking site for MDM2,

134 The tumor suppressor protein p53 contributes to the control of cell cycle che

135 ly, we show that Na and the tumor suppressor protein p53 cooperate to induce lytic gene expression in

136 Here we show that the tumor suppressor protein p53 cooperates with DNA methylation to maintain

137 The tumor suppressor protein p53 coordinates the cellular response to stress

138 mutations occurring in the tumour suppressor protein p53, demonstrating the applicability of the prop

139 nsic apoptotic pathway in a tumor suppressor protein p53-dependent manner.

140 disorder-cytochrome c, the tumor suppressor protein p53 DNA binding domain (p53 DBD), and the N-term

141 The tumor suppressor protein p53 down-regulates a number of genes, including

142 of Ku80 along with the cell cycle checkpoint protein, p53, dramatically increases the incidence of pr

143 on the conjugation of SUMO-1 with the target proteins p53, E1B, and promyelocytic leukemia protein an

144 ct that is dependent on the tumor suppressor protein p53 (encoded by Trp53 in mice) and is characteri

145 protein Myc, or loss of the tumor suppressor protein p53 (encoded by Trp53 in mice) further accelerat

146 eceptor alpha (ERalpha) and tumor suppressor protein p53 exert opposing effects on cellular prolifera

147 The tumor suppressor protein p53 exhibits high affinity to the response eleme

148 Under normal conditions, tumor suppressor protein p53 exists in the cell in its latent form and is

149 evious assumptions that the tumor suppressor protein p53 exists primarily and functionally as a singl

150 ibe the oxidation of a cell-cycle regulatory protein, p53, from a distance through DNA-mediated CT.

151 The tumor suppressor protein p53 functions as a transcriptional factor that a

152 ate dehydrogenase (GAPDH), and the recycling protein p53/gp58.

153 -alpha, an inhibitor of the tumor suppressor protein p53, had no effect on ROS generation but did blo

154 mothripsis, and a simpler genotype, WT tumor protein p53, had relatively few SNVs (average of 5.9 per

155 Since the tumor suppressor protein p53 has been implicated in apoptosis in a large

156 The tumor suppressor protein p53 has been implicated in the response of cells

157 The tumor suppressor protein p53 has been well documented as a transcriptiona

158 The tumour-suppressor protein p53 has then been compared with the non-redundan

159 2 (HDM2), which binds to and inactivates the protein p53, has been linked to tumor aggressiveness and

160 he roles and actions of the tumor suppressor protein p53 have been extensively studied with regard to

161 The TATA binding protein, p53, histone deacetylase-1 and mSin3a could be

162 pidermal patches that stain positive for p53 protein (p53 immunopositive patches, PIPs), which are co

163 reast cancer cells, whereas tumor suppressor protein p53 impedes proliferation of cells with genomic

164 PA alters expression of the tumor suppressor protein p53 in Beas2B airway epithelial cells in both a

165 d to detect unlabeled human tumor suppressor protein p53 in crude lysates, without any purification s

166 Lysine acetylation of the tumor suppressor protein p53 in response to a wide variety of cellular st

167 14-3-3 sigma is induced by tumor suppressor protein p53 in response to DNA damage.

168 ription target of the human tumor-suppressor protein p53 in signaling apoptosis and growth suppressio

169 the tetramers formed by the tumor suppressor protein p53 in single living cells.

170 of evidence implicating the tumor suppressor protein p53 in terminal differentiation of the renal epi

171 d its role in anchoring the tumor suppressor protein p53 in the cytoplasm reveals yet another level o

172 Tumor protein p53-induced nuclear protein 1 (TP53INP1) is invo

173 The tumor suppressor protein p53 induces or represses the expression of a var

174 It depends on the growth regulator p53 and a protein p53 induces, the cyclin dependent kinase inhibit

175 er and CCCH-type domain 1 (RC3H1), and tumor protein p53-inducible protein 11 (TP53I11) interacted wi

176 E1B-55kDa and E4orf6 to the tumor suppressor protein p53 inhibits its transcriptional activity and ca

177 The multifunctional tumor suppressor protein, p53, inhibits cell growth and promotes differen

178 biquitinate and degrade the tumor suppressor protein p53, involving interactions with the N-terminal

179 Improper function of the tumor suppressor protein p53 is a contributing factor in many human cance

180 The protein p53 is a critical tumor suppressor, as demonstra

181 The major tumor suppressor protein p53 is a key cell regulator involved in cell pro

182 The tumor suppressor protein p53 is a pivotal regulator of apoptosis, and pro

183 The tumor suppressor protein p53 is a transcription factor that is frequently

184 The tumor suppressor protein p53 is a transcription factor that is mutated in

185 The tumor suppressor protein p53 is a transcription factor that regulates apo

186 The tumor suppressor protein p53 is a transcription factor that regulates the

187 Because tumor suppressor protein p53 is also a redox active transcription factor

188 M2 and MDMX to activate the tumor suppressor protein p53 is an attractive therapeutic paradigm for th

189 The tumor suppressor protein p53 is an essential molecule in cell proliferati

190 The tumour-suppressor protein p53 is an important activator of apoptosis.

191 The tumor suppressor protein p53 is emerging as a central regulator of homolo

192 s study, we report that the tumor suppressor protein p53 is essential for the induction of cell death

193 he transcription factor and tumor suppressor protein p53 is frequently inactivated in human cancers.

194 The tumor suppressor protein p53 is frequently inactivated in tumors.

195 The tumor suppressor protein p53 is inactivated by mutation in about half of

196 al cellular conditions, the tumor suppressor protein p53 is kept at low levels in part due to ubiquit

197 The tumor suppressor protein p53 is known to be transported to the nucleus al

198 The tumor suppressor protein p53 is known to induce either apoptosis or growt

199 The tumour suppressor protein p53 is localized in the cell nucleus where it se

200 The tumor suppressor protein p53 is mutated in over half of human cancers.

201 In unstressed cells, the tumor suppressor protein p53 is present in a latent state and is maintain

202 Because the protein p53 is required for cell death induced by oxidat

203 The tumour suppressor protein p53 is stabilised and activated in response to i

204 As a key cellular regulatory protein p53 is subject to tight regulation by several E3

205 he C-terminal domain of the tumor suppressor protein p53 is the site of non-specific DNA binding.

206 The tumor-suppressor protein p53 is tightly controlled in normal cells by its

207 cells, the function of the tumor suppressor protein p53 is usually blocked.

208 As a shuttling protein, p53 is constantly transported through the nucle

209 Among such proteins, p53 is known to respond to DNA damage by accum

210 er the tumor suppressor TP53 (coding for the protein p53) is hypermutable at some stage of carcinogen

211 The TP53 gene, encoding tumour suppressor protein p53, is located on the short arm of chromosome 1

212 fecter of this pathway, the tumor suppressor protein p53, is tightly regulated by controlled degradat

213 provides evidence that the tumor suppressor protein, p53, is a transcriptional repressor of PKD1.

214 Tumor suppressor protein, p53, is an intracellular protein that is critic

215 The tumor suppressor protein, p53, is either mutated or absent in >50% of can

216 The oncogene suppressor protein, p53, is serine phosphorylated by several kinase

217 The tumor suppressor protein p53 localizes to microtubules (MT) and, in respo

218 Because the tumor suppressor protein p53 may be involved in these effects, we have in

219 The tumor suppressor protein p53 may have other roles and functions in additi

220 rate the potential biological role of the TS protein-p53 mRNA interaction, Western immunoblot analysi

221 Variability in the bcl-2 family of proteins, p53 mutation, or the presence of various chrom

222 All three had tumor protein p53 mutations and a relatively large number of s

223 ns in cultured cancer cells with TP53 (tumor protein p53) mutations, in cells from patients with nons

224 lly dependent inhibition of tumor suppressor protein p53, normalization of the pro-apoptotic Bax/Bcl-

225 ked hyperacetylation of the tumor suppressor protein p53 on lysine 370, 379 and 383; these post-trans

226 , ATR phosphorylates the genome surveillance protein p53 on serine 15, a site which is up-regulated i

227 The tumor suppressor protein p53, once activated, can cause either cell cycle

228 uld be altered by depleting tumor suppressor protein p53 or its transcriptional target p21(CIP/WAF).

229 lls deficient in either the tumor suppressor proteins p53 or Bax, apoptosis was least affected in the

230 Moreover, knocking down tumor suppressor proteins p53 or pRB using small interfering RNA signific

231 Tumor suppressor protein p53, our most critical defense against tumorigen

232 of key cell cycle regulators (retinoblastoma protein, p53, p21(waf1/Cip1), and p16(INK4A)), and senes

233 onally dead variant of the tumour-suppressor protein p53 (p53(25,26,53,54)), along with a wild-type a

234 that none of the 27 patients with both tumor protein p53 (p53) and v-Ki-ras2 Kirsten rat sarcoma vira

235 ivation domain of the human tumor suppressor protein p53 (p53TAD) and the 70 kDa subunit of human rep

236 tain coat protein I (COPI) and the recycling protein p53/p58, suggesting that the vesicles traffic in

237 The tumor suppressor protein p53 participates in DNA repair and cell cycle re

238 synthetic inhibitors of the tumor suppressor protein p53, pifithrin-alpha (PFT-alpha) and Z-1-117, ar

239 The tumor suppressor protein p53 plays a central role in modulating the cellu

240 The tumor suppressor protein p53 plays a central role in protecting normal ce

241 The tumor suppressor protein p53 plays a central role in tumor prevention.

242 Although tumor suppressor protein p53 plays a critical role in the elimination of

243 The tumor suppressor protein p53 plays a crucial role in coordinating cellula

244 The tumor suppressor protein p53 plays a key role in maintaining the genomic

245 The tumor suppressor protein p53 plays an important role in maternal reproduc

246 The tumor suppressor protein, p53, plays a critical role as a transcriptional

247 The tumor suppressor protein, p53, plays a critical role in mediating cellula

248 The tumor suppressor protein p53 regulates numerous signaling pathways by spe

249 The tumor suppressor protein p53 regulates transcriptional programs that cont

250 The tumor suppressor protein p53 regulates various cellular responses to DNA

251 udies revealed two unique functions for this protein: p53 regulates cellular energy metabolism and an

252 hich it cooperates with the tumor suppressor protein p53, remain poorly understood.

253 types of DNA lesions by the tumor suppressor protein, p53, represents one of the several downstream f

254 Rapid turnover of the tumor suppressor protein p53 requires the MDM2 ubiquitin ligase, and both

255 by demethylating histone and the non-histone protein p53, respectively.

256 o stressful conditions, the tumor suppressor protein p53 restrains growth by promoting an arrested ce

257 ncrease the activity of the tumor suppressor protein p53, resulting in cell cycle arrest.

258 lowed by phosphorylation of tumor suppressor protein p53 Ser 15 at 3 to 6 h p.i., stabilizing p53 lev

259 that NPCs deficient in the tumor suppressor protein p53 show significantly less death after exposure

260 y of stimuli, including the tumor suppressor protein p53, that can mediate cell cycle arrest through

261 The tumor suppressor protein p53, the "guardian of the genome", is inactivate

262 eems to form a complex with tumor suppressor protein p53, thereby enhancing its intracellular level t

263 forming a complex with the tumour-suppressor protein p53, thereby stabilizing it and enhancing its fu

264 l fibroblasts that lack the tumor-suppressor protein p53 through a paracrine mechanism.

265 large regions of the human tumor suppressor protein p53 to identify single amino-acid substitutions

266 The ability of the tumor suppressor protein, p53, to recognize certain types of DNA lesions

267 Mutations in the tumor protein p53 (TP53) are the most frequently occurring gen

268 the effects for SNP309 and the related tumor protein p53 (TP53) Arg72Pro are inconsistent among publi

269 ma viral oncogene homolog B (BRAF) and tumor protein p53 (TP53) mutations cooccur in a high proportio

270 arcomatoid elements acquired biallelic tumor protein p53 (TP53) mutations in 32% of tumors (P = 5.47

271 cancers, TDP tumors conjointly exhibit tumor protein p53 (TP53) mutations, disruption of breast cance

272 d at 17p13, only 500-kb centromeric of tumor protein p53 (Tp53), and is codeleted with Tp53, we propo

273 emonstrates the involvement of BCL6 in tumor protein p53 (TP53), erythroblastic leukemia viral oncoge

274 DNA damage transactivates tumour protein p53 (TP53)-regulated surveillance, crucial in su

275 he expression of the mutant tumor suppressor protein p53 (Tp53).

276 primary mouse epithelial cells lacking tumor protein p53 (TP53, best known as p53) in the presence of

277 ating cell nuclear antigen, tumor suppressor protein p53, transcription factor NF-kappaB p50 and its

278 with somatic loss of transformation-related protein p53 (Trp53) function and/or overexpression of hu

279 at, together with a variety of other nuclear proteins, p53 undergoes extensive poly(ADP-ribosyl)ation

280 ed expression of Bcl-2 homology 3 (BH3)-only protein p53 up-regulated modulator of apoptosis (PUMA),

281 vels of p53 and the p53-related proapoptotic proteins p53-up-regulated modulator of apoptosis (PUMA)

282 mulation and acetylation of tumor suppressor protein p53 upon the cell cycle entry of hair follicle e

283 The Bcl homology-3 (BH3)-only protein p53 upregulated modulator of apoptosis (PUMA) co

284 ently showed a critical role of the BH3-only protein p53 upregulated modulator of apoptosis (PUMA) in

285 heckpoint protein p21, but not the apoptotic protein p53-upregulated modulator of apoptosis.

286 ng degradation of the pro-apoptotic BH3-only protein p53-upregulated modulator of apoptosis.

287 ondrial dysfunction and the tumor suppressor protein p53 using a set of respiration-deficient (Res(-)

288 The tumor suppressor protein, p53, utilizes multiple mechanisms to ensure fai

289 type activation of temperature-sensitive p53 protein (p53 val) at permissive temperature in M1-t-p53

290 lation of the pro-apoptotic tumor suppressor protein, p53, via PKB-mediated phosphorylation of MDM2 m

291 he intrinsically disordered tumor suppressor protein p53 was analyzed by using a combination of ion m

292 Protein p53 was determined using an enzyme-linked immuno

293 ound that expression of the tumor suppressor protein p53 was higher in MCH(-/-) mice at 9 and 19 mont

294 t negative regulator of the tumor suppressor protein p53 which regulates the expression of many genes

295 negative regulators of the tumor suppressor protein p53, which are frequently upregulated in cancer

296 gest a novel mechanism by which the cellular protein p53, which is involved in both transcriptional r

297 poptosis independent of the tumor suppressor protein p53, which primarily affects DNA damage-induced

298 cytomegalovirus (HCMV), the tumor suppressor protein p53, which promotes efficient viral gene express

299 in the nuclear level of the tumor suppressor proteins p53 (wild type), pRb, and p130/Rb2 and of the p

300 a rapid accumulation of the tumor-suppressor protein p53 within target cells, which seems to be invol